Navigation Links
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
Date:3/22/2013

HAYWARD, Calif., March 22, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced its abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus Erythematosus," has been selected as an oral presentation and will be presented at the 10th International Congress on Systemic Lupus Erythematosus by Dr. Morton Scheinberg , a rheumatologist at the Hospital Abreu Sodre Pesquisa Clinica in Sao Paulo, Brazil, on April 20, 2013.

Additionally, a poster entitled "Clinical Experience in Latin America With Blisibimod Amongst Subjects with Active, Moderate-to-Severe Systemic Lupus Erythematosus: Data From The Phase 2b PEARL-SC Study," will be presented by Dr. Scheinberg as part of the conferences Guided Poster Tours on April 19, 2013.

The poster will be available on www.anthera.com.

About Blisibimod and PEARL-SC

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy, immune thrombocytopenic purpura and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF inhibitors potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a selective inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.  The PEARL-SC Phase 2 study was designed as a ran
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
2. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
3. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
7. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
8. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
9. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
10. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/28/2015)... -- The global mHealth market ... 2020, growing at a CAGR of 47.6% from 2013 ... View Research, Inc. Monitoring services is expected to grow ... 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... of chronic diseases such as cancer, heart ailments, and ...
(Date:8/27/2015)... WASHINGTON , Aug. 27, 2015 ... Collaborative (BPC) applauds the U.S. Food and Drug ... a distinguishable name in its draft guidance issued ... of biological products proposes distinguishable names, calling for ... includes an FDA-designated suffix. This proposal reflects the ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Dec. 5, 2011  At this week,s 46th Annual Midyear ... Health-System Pharmacists (ASHP), Cardinal Health launched BarCode360™ , ... making it easier, more timely and cost efficient to ... scanned at the patient bedside. ASHP has ...
... Pharmaceutical Co. Ltd, in which European healthcare venture capital ... as one of the Deloitte & Touche,s 50 top-performing ... the past three years. Beijing-headquartered GC-Rise, which ... revenues rising more than 270% on average per annum ...
Cached Medicine Technology:Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 2Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 3Women Health Expert GC-Rise Listed in Deloitte's 50 Top-performing Companies 2
(Date:8/28/2015)... ... August 28, 2015 , ... SmartPractice Calendars ... Personalized with practice contact information and logos, Calendars stand alone as functional brand-building ... Calendars into seasonal mailings, thank you and welcome communications, and to complement statements ...
(Date:8/28/2015)... ... 28, 2015 , ... SharkNinja, an innovative leader in the ... actress, Sofia Vergara, and unveil the Ninja® brand’s new coffee machine, the ... a variety of sizes and styles while achieving the perfect brew richness level ...
(Date:8/28/2015)... ... August 28, 2015 , ... Researchers ... comprehensive information on two new duals programs: Rhode Island Integrated Care Initiative, ... Idaho’s partnership to revamp Blue Cross of Idaho’s D-SNP. The database also ...
(Date:8/28/2015)... ... 28, 2015 , ... The Plaintiffs Steering Committee (PSC) and ... Replacement Therapy Products Liability Litigation, are in the midst of ongoing discussion regarding ... may receive for corporate employees involved in the production or marketing of AbbVie ...
(Date:8/28/2015)... ... ... Super-Sod launched their new website this summer. The new user-friendly site ... responsive web design. Website users will now have an improved browsing experience on their ... sign-up for the monthly turf-tips email, and find a local Super-Sod store all from ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4
... HealthDay Reporter , MONDAY, Sept. 5 (HealthDay ... may be creeping into the U.S. blood supply and ... researchers report. , Babesiosis is a parasitic infection that ... blood transfusion. Symptoms range from mild flu-like symptoms to ...
... University,s Mailman School of Public Health heightens concerns over ... of ubiquitous chemicals known as phthalates. Phthalates are a ... endocrine system, and are widely used in consumer products ... shampoos. Recent studies of school-age children have provided ...
... PAUL, Minn. Psychogenic non-epileptic seizures may go undiagnosed for much ... study published in the September 6, 2011, print issue of ... of Neurology. This type of seizure is different from seizures ... origin. "People with psychogenic seizures are often diagnosed with ...
... in a study published in the Archives of General Psychiatry ... serotonin (a brain chemical related to mood), may serve as ... stress disorder (PTSD) following a trauma. "One of ... at risk for developing the disorder following a trauma, while ...
... Reporter , MONDAY, Sept. 5 (HealthDay News) -- Growing ... vaccines, which could indicate that resistance to children,s inoculations ... getting better, but we still have a fair way ... immunization services division at the National Center for Immunization ...
... , MONDAY, Sept. 5 (HealthDay News) - Rudeness ... the workplace, a new study shows. Researchers from Baylor ... that stress home with them, which can have negative effects ... jobs. The researchers explained that when employees go home ...
Cached Medicine News:Health News:Tick-borne Illness May Lurk in Blood Supply 2Health News:Tick-borne Illness May Lurk in Blood Supply 3Health News:Prenatal exposure to phthalates linked to decreased mental and motor development 2Health News:Non-epileptic seizures may be misdiagnosed longer in veterans 2Health News:The search for predictors of risk for PTSD 2Health News:More U.S. 'Tweens' Getting Recommended Vaccines 2Health News:More U.S. 'Tweens' Getting Recommended Vaccines 3Health News:Boorish Co-Workers Can Damage Your Home Life 2
... The Chemcard Glucose Test is a simple, ... abnormally high fasting plasma glucose (blood sugar) levels ... Chemcard Glucose is a 3 minute test which ... a fingerstick, requires no instruments, and was shown ...
The Lifestream Plus Cholesterol Monitor provides you with a comprehensive tool to help you monitor your cholesterol as part of your wellness program....
CardioChek™ PA Portable Whole Blood Test System...
... A(ll) Test is a lateral ... rapid, qualitative detection of Group ... swabs. The test is intended ... in the diagnosis of Group ...
Medicine Products: